Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
Public ClinicalTrials.gov record NCT02600611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1
Study identification
- NCT ID
- NCT02600611
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Motif Bio
- Industry
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Interventions
- iclaprim Drug
- vancomycin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015
- Primary completion
- Jan 29, 2017
- Completion
- Jan 29, 2017
- Last update posted
- Jun 18, 2018
2015 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California | Buena Park | California | 90620 | — |
| California | La Mesa | California | 91942 | — |
| California | Long Beach | California | 90806 | — |
| California | Modesto | California | 95350-449 | — |
| California | Oceanside | California | 92056 | — |
| California | Torrance | California | 90503 | — |
| District of Columbia | Washington D.C. | District of Columbia | 20017 | — |
| Florida | DeLand | Florida | 32770-0834 | — |
| Florida | Miami | Florida | 33144 | — |
| Indiana | Indianapolis | Indiana | 46260 | — |
| Nebraska | Lincoln | Nebraska | 68510-2462 | — |
| Tennessee | Franklin | Tennessee | 37067 | — |
| Tennessee | Franklin | Tennessee | 37094 | — |
| Texas | Channelview | Texas | 77530 | — |
| Texas | McAllen | Texas | 78503 | — |
| Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02600611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02600611 live on ClinicalTrials.gov.